Hosted on MSN
Over the past decade, early-stage drug innovation has shifted toward China, researchers find
In 2015, about 48% of early-stage programs originated in the U.S. and 8% in China. By 2024, the U.S. share had declined to just over 37%, while China's share rose to just over 32%. Overall, the number ...
As we approach 2026,late-stage programs across key therapeutic areas are poised to reshape treatment paradigms. Driven by novel mechanisms, first-in-class targets and more convenient administration ...
WASHINGTON — Early-stage drug development worldwide has nearly doubled over the past decade and shifted from a U.S.-dominated model to a dual hub centered in the United States and China, according to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results